Valuation: Fulgent Genetics, Inc.

Market Cap 574M 499M 464M 426M 805M 54.79B 818M 5.47B 2.15B 27.28B 2.16B 2.11B 91.47B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 574M 499M 464M 426M 805M 54.79B 818M 5.47B 2.15B 27.28B 2.16B 2.11B 91.47B EV / Sales 2026 *
1.63x
EV / Sales 2027 * 1.43x
Free-Float
52.29%
Yield 2026 *
-
Yield 2027 * -
1 day-18.11%
1 week-15.86%
Current month-19.35%
1 month-20.51%
3 months+17.13%
6 months-36.64%
Current year-37.00%
1 week 16.05
Extreme 16.0501
20.27
1 month 16.05
Extreme 16.0501
21.59
Current year 13.46
Extreme 13.46
28.95
1 year 13.46
Extreme 13.46
31.04
3 years 13.46
Extreme 13.46
44.09
5 years 13.46
Extreme 13.46
112
10 years 2.72
Extreme 2.725
189.89
Manager TitleAgeSince
President 59 03/05/2022
Chief Executive Officer 70 13/05/2016
Director of Finance/CFO 58 01/01/2016
Director TitleAgeSince
Chairman 70 01/09/2016
Director/Board Member 76 01/08/2019
Director/Board Member 57 01/08/2022
Date Insider Type Main position Quantity % Market Cap.
7/26/26 A Tax

Chief Financial Officer

-2,747 0.0090%
7/26/26 A Tax

Founder

-4,361 0.0142%
7/26/26 A Tax

Chief Technology Officer

-1,645 0.0054%
Change 5-day change 1-year change 3-year change Capi.($)
-18.11%-15.86%-3.67%-57.38% 574M
-0.70%+2.20%+100.33%+492.13% 38.62B
-2.01%+4.19%+18.89%+44.53% 25.53B
-2.84%+5.10%-21.08%-37.40% 7.79B
+1.74%+3.59%+16.54%+92.81% 4.93B
+1.41%+12.93%+22.95%+61.82% 3.29B
-3.72%+10.08%+215.91%-11.77% 2.04B
-5.58%+10.17%-36.14%+778.68% 2.05B
+2.28%+4.68%-9.46%-61.46% 1.86B
+11.30%+5.41%+19.44%+6.39% 1.82B
Average -1.62%+2.85%+32.37%+130.84% 8.85B
Weighted average by Cap. -1.04%+2.25%+53.47%+248.00%

Financials

2026 *2027 *
Net sales 352M 306M 285M 262M 494M 33.62B 502M 3.36B 1.32B 16.74B 1.32B 1.29B 56.13B 402M 349M 325M 298M 564M 38.35B 572M 3.83B 1.5B 19.09B 1.51B 1.48B 64.01B
Net income -90M -78.24M -72.82M -66.86M -126M -8.59B -128M -858M -337M -4.28B -338M -331M -14.34B -73M -63.46M -59.07M -54.23M -102M -6.97B -104M -696M -273M -3.47B -274M -268M -11.63B
Net Debt - -
Logo Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Employees
1,315
Date Price Change Volume
31/07/26 $16.55 -18.11% 1,319,767
30/07/26 $20.21 +2.90% 277,726
29/07/26 $19.64 +0.05% 217,089
28/07/26 $19.63 +0.26% 260,082
27/07/26 $19.58 -0.46% 221,329
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
20.21USD
Average target price
15.00USD
Spread / Average Target
-25.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FLGT Stock